Delcath Systems to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
Delcath Systems (Nasdaq: DCTH), a company specializing in interventional oncology for liver cancer treatment, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for Wednesday, September 11, 2024, at 11:00 a.m. Eastern Time. Delcath's management team will engage in a fireside chat during the conference, which will take place at the Lotte New York Palace Hotel in New York City.
This participation provides an opportunity for Delcath Systems to showcase its focus on treating primary and metastatic liver cancers to potential investors and industry professionals. The H.C. Wainwright conference is a significant platform for companies in the healthcare and life sciences sectors to present their latest developments and strategies.
Delcath Systems (Nasdaq: DCTH), un'azienda specializzata in oncologia interventistica per il trattamento del cancro al fegato, ha annunciato la sua partecipazione alla 26a Conferenza Globale Annuale sugli Investimenti H.C. Wainwright. L'evento si terrà mercoledì 11 settembre 2024, alle 11:00 ora orientale. Il team di gestione di Delcath parteciperà a un fireside chat durante la conferenza, che si svolgerà presso il Lotte New York Palace Hotel a New York City.
Questa partecipazione offre a Delcath Systems l'opportunità di mettere in evidenza il suo impegno nel trattamento dei tumori epatici primari e metastatici di fronte a potenziali investitori e professionisti del settore. La conferenza H.C. Wainwright rappresenta una piattaforma significativa per le aziende nei settori della salute e delle scienze della vita per presentare i loro ultimi sviluppi e strategie.
Delcath Systems (Nasdaq: DCTH), una empresa especializada en oncología intervencionista para el tratamiento del cáncer de hígado, ha anunciado su participación en la 26ª Conferencia Anual Global de Inversiones H.C. Wainwright. El evento está programado para el miércoles 11 de septiembre de 2024, a las 11:00 a.m., hora del Este. El equipo directivo de Delcath participará en un fireside chat durante la conferencia, que tendrá lugar en el Lotte New York Palace Hotel en la ciudad de Nueva York.
Esta participación brinda a Delcath Systems la oportunidad de mostrar su enfoque en el tratamiento del cáncer de hígado primario y metastásico ante posibles inversores y profesionales del sector. La conferencia H.C. Wainwright es una plataforma significativa para que las empresas en los sectores de salud y ciencias de la vida presenten sus últimos desarrollos y estrategias.
Delcath Systems (Nasdaq: DCTH), 간암 치료를 전문으로 하는 중재적 종양학 회사가 H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에 참여한다고 발표했습니다. 이 행사는 2024년 9월 11일 수요일 오전 11시(동부 표준시)에 예정되어 있습니다. Delcath의 경영진 팀은 화로 옆 담화에 참여할 예정이며, 이는 뉴욕시의 Lotte New York Palace Hotel에서 열릴 예정입니다.
이번 참여는 Delcath Systems에게 1차 및 전이성 간암 치료에 대한 초점을 잠재적인 투자자 및 업계 전문가들 앞에 선보일 기회를 제공합니다. H.C. Wainwright 컨퍼런스는 헬스케어 및 생명과학 분야의 기업들이 최신 개발 및 전략을 발표할 수 있는 중요한 플랫폼입니다.
Delcath Systems (Nasdaq: DCTH), une entreprise spécialisée dans l'oncologie interventionnelle pour le traitement du cancer du foie, a annoncé sa participation à la 26e Conférence Annuelle Mondiale d'Investissement H.C. Wainwright. L'événement est programmé pour mercredi 11 septembre 2024, à 11h00 heure de l'Est. L'équipe de direction de Delcath participera à un fireside chat lors de la conférence, qui se déroulera dans le Lotte New York Palace Hotel à New York.
Cette participation offre à Delcath Systems l'opportunité de mettre en avant son engagement envers le traitement des cancers du foie primaires et métastatiques devant des investisseurs potentiels et des professionnels de l'industrie. La conférence H.C. Wainwright représente une plateforme significative pour les entreprises des secteurs de la santé et des sciences de la vie pour présenter leurs derniers développements et stratégies.
Delcath Systems (Nasdaq: DCTH), ein Unternehmen, das sich auf interventionelle Onkologie zur Behandlung von Leberkrebs spezialisiert hat, gab seine Teilnahme an der 26. jährlichen globalen Investmentkonferenz von H.C. Wainwright bekannt. Die Veranstaltung findet am Mittwoch, den 11. September 2024, um 11:00 Uhr Eastern Time statt. Das Management-Team von Delcath wird während der Konferenz an einem Fireside Chat teilnehmen, der im Lotte New York Palace Hotel in New York City stattfinden wird.
Diese Teilnahme bietet Delcath Systems die Möglichkeit, sein Augenmerk auf die Behandlung von primären und metastatischen Leberkrebserkrankungen gegenüber potenziellen Investoren und Fachleuten der Branche zu präsentieren. Die H.C. Wainwright-Konferenz ist eine bedeutende Plattform für Unternehmen im Gesundheits- und Lebenswissenschaftssektor, um ihre neuesten Entwicklungen und Strategien vorzustellen.
- None.
- None.
About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure.
In
In
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828316176/en/
Investor Relations Contact:
ICR Westwicke
investorrelations@delcath.com
Source: Delcath Systems, Inc.
FAQ
When is Delcath Systems (DCTH) participating in the H.C. Wainwright Global Investment Conference?
Where will the H.C. Wainwright conference featuring Delcath Systems (DCTH) be held?
What type of presentation will Delcath Systems (DCTH) give at the H.C. Wainwright conference?
What is the main focus of Delcath Systems (DCTH) as mentioned in the press release?
